# Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer

> **NCT00005648** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 688 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Gemcitabine with R115777
- **DRUG:** Gemcitabine with Placebo

## Key facts

- **NCT ID:** NCT00005648
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** —
- **Final completion:** 2003-11
- **Target enrollment:** 688 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005648, "Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*